Tabula Rasa HealthCare (NASDAQ:TRHC)‘s stock had its “buy” rating reissued by Chardan Capital in a report released on Friday, Marketbeat.com reports. They currently have a $50.00 price target on the stock, up from their previous price target of $46.00. Chardan Capital’s price target would indicate a potential upside of 39.74% from the company’s current price.
Several other research analysts have also recently issued reports on the company. Zacks Investment Research cut Tabula Rasa HealthCare from a “hold” rating to a “sell” rating in a research note on Tuesday, January 2nd. BidaskClub cut Tabula Rasa HealthCare from a “buy” rating to a “hold” rating in a research note on Friday, December 15th. Oppenheimer initiated coverage on Tabula Rasa HealthCare in a research note on Monday, December 18th. They issued an “outperform” rating and a $35.00 price objective for the company. Citigroup initiated coverage on Tabula Rasa HealthCare in a research note on Thursday, January 4th. They issued a “buy” rating for the company. Finally, William Blair initiated coverage on Tabula Rasa HealthCare in a research note on Monday, December 11th. They issued an “outperform” rating for the company. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and ten have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $36.40.
Shares of Tabula Rasa HealthCare (NASDAQ TRHC) opened at $35.78 on Friday. The company has a quick ratio of 0.66, a current ratio of 1.21 and a debt-to-equity ratio of 0.01. Tabula Rasa HealthCare has a 12 month low of $11.59 and a 12 month high of $39.81. The company has a market capitalization of $672.85, a PE ratio of 51.86, a price-to-earnings-growth ratio of 7.47 and a beta of 3.60.
In related news, CFO Brian W. Adams bought 5,391 shares of the company’s stock in a transaction that occurred on Friday, January 12th. The shares were purchased at an average cost of $14.23 per share, with a total value of $76,713.93. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Bruce Luehrs sold 16,745 shares of the firm’s stock in a transaction dated Tuesday, March 13th. The stock was sold at an average price of $37.63, for a total value of $630,114.35. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 311,766 shares of company stock worth $10,797,424. 45.80% of the stock is owned by corporate insiders.
Institutional investors have recently bought and sold shares of the stock. Wells Fargo & Company MN grew its holdings in Tabula Rasa HealthCare by 79.8% during the third quarter. Wells Fargo & Company MN now owns 12,768 shares of the company’s stock worth $341,000 after acquiring an additional 5,668 shares during the period. JPMorgan Chase & Co. acquired a new stake in Tabula Rasa HealthCare during the third quarter worth about $563,000. EAM Investors LLC grew its holdings in Tabula Rasa HealthCare by 21.5% during the fourth quarter. EAM Investors LLC now owns 178,588 shares of the company’s stock worth $5,009,000 after acquiring an additional 31,596 shares during the period. Vanguard Group Inc. grew its holdings in Tabula Rasa HealthCare by 13.4% during the second quarter. Vanguard Group Inc. now owns 236,964 shares of the company’s stock worth $3,566,000 after acquiring an additional 27,997 shares during the period. Finally, Quadrant Private Wealth Management LLC acquired a new stake in Tabula Rasa HealthCare during the fourth quarter worth about $569,000. 53.03% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This report was first published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at https://www.chaffeybreeze.com/2018/03/16/chardan-capital-raises-tabula-rasa-healthcare-trhc-price-target-to-50-00.html.
Tabula Rasa HealthCare Company Profile
Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.
Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.